Obesity Management Market Size

Global Obesity Management Market Overview

Obesity Management Market Size was valued at USD 121.69billion in 2021 and is projected to grow from USD 132.89 billion in 2022 to USD 2.85 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.4% during the forecast period (2023 - 2032).The growing rate of bariatric surgery, rise in adoption of unhealthy and sedentary lifestyle patterns and increasing awareness about weight management are driving the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review 

Because of sedentary lives and poor eating practices in recent years, obesity has become an international problem. Technologies and drugs that assist obese or overweight people in losing or maintaining their weight are included in the obesity management market. Obesity is a long-term medical condition characterized by abnormal fat deposition and buildup in the body. The Body Mass Index (BMI) calculates it (BMI). Some of the methods used to address losing weight and obesity include prescription medications, dietary supplements, weight-reduction surgery, and exercise. In North America, one in three adults suffers from obesity. Numerous chronic disorders linked to obesity can be prevented with appropriate weight management. According to the AHA, obese patients should be managed for the first phase of hypertension by decreasing weight through dietary changes, medication, and bariatric surgery. Additionally, it is anticipated that the increased popularity of junk foods and bad, sedentary lifestyle patterns would fuel market expansion. Factors including a busy schedule, physical inactivity, and rising stress also support the market's expansion.

Additionally, the rise in bariatric surgeries, the expansion of fitness facilities, and the rising popularity of online weight reduction and weight management courses all restrain market growth throughout the anticipated time. Factors driving the market growth include the rise in the number of bariatric procedures, the expansion of government initiatives to increase public awareness regarding weight management, the rapid adoption of online weight loss & management products and services, the rise in disposable income in developing countries, as well as the increase in cases of weight gain brought on by sedentary lifestyles. The cost of treatments and medications might make treating obesity challenging. Surgery for weight loss is not well-reimbursed in developing nations. Medical payers are reluctant to offer payment since weight control is time-consuming. A few treatments have made it to the market, and worries about the efficacy of obesity management medications are stalling clinical trials. Certain drug formulations have the potential to cause cancer or cardiovascular disease. These occurrences could lead to drug recalls.

Ahead with Alpha, a weight-management program for employers, was introduced by Hello Alpha. It provides access to primary care doctors with experience treating obesity, weight reduction pharmaceutical management using GLP-1s, registered dietitian dietary counseling, and progress monitoring. The Palo Alto, California-based business introduced Ahead with Alpha this week, which helps with weight loss to staff members of its employer clients. This assistance includes getting in touch with general practitioners skilled in treating obesity, managing your medications with weight-loss medications like GLP-1s, getting nutrition advice from a certified dietician, and keeping track of your progress.

In March, 2023, PRISTYN CARE made official that it has made a strategic collaboration with Allurion to create a weight loss and obesity care platform.

For example, Viking Therapeutics indicated the launch of Phase I clinical trials for its anti-obesity formulations on VK2735—an investigational dual glucagon-like peptide 1 (GLP-1) & glucose-dependent insulinotropic polypeptide (GIP) receptor agonist In March 2023

In December 2022, Amgen Inc. made pubilc regarding their new phase 1 data of AMG133, that is a latest bispecific GIPR antagonist and GLP-1 receptor agonist molecule.

For instance, brands are adding natural ingredients, caffeine and low-sugar contents to RTD products. For example, in April 2022, Life Extension launched Waistline Control, which helps reduce waistline sizes.

Apple introduced Fitness+ during September 2020 as an excellent way for users to see on their iPhone or, iPad or Apple TV the metrics from their Apple Watch; presenting the user experience first personalized workout session like no other.

In March 2020, CoreX Fit Life created CoreX, which is the only fitness machine in such small size that can give over hundreds of exercises as well as sports simulation. CoreX offers cardio workouts for more than hundred exercises, including HIIT strength training, Pilates toning etc.

According to Vivus Inc.’s press release in February 2020, Alvogen introduced Qsymia (phentermine and topiramate elongated) into the Republic of Korea.

Obesity Management Market Trends

• Growing rate of bariatric surgery to boost market growth

Bariatric surgery is a weight loss surgery that involves making changes to the digestive system in order to lose weight. It limits the food intake of the body and decreases the absorption of food in the stomach and intestines. After excessive dieting, exercise, and obesity treatments, many choose bariatric surgeries. Weight-loss programs are difficult for obese individuals. Previously, weight loss surgeries were painful, and adoption of these procedures was significantly lower before a few years.However, today's technological advancements make these surgeries less painful. For instance, according to the American Society for Metabolic and Bariatric Surgery, in 2020, around 199,000 metabolic and bariatric surgeries were performed in the US.

Obesity rates are rising at an exponential pace. According to the World Obesity Atlas Report 2022, it is estimated that around one billion people will be obese globally by 2030. This report also estimates that 1 in 7 men and 1 in 5 women will be obese worldwide by 2030. Today, obesity is considered a major disorder that can lead to chronic illnesses. Also, the need to reduce weight for a better and healthier lifestyle is encouraging obese patients to adopt management programs. This is creating demand for bariatric surgeries. The growth of bariatric surgical equipment is bringing favorable changes to the obesity management market. Also, rising awareness about obesity management is another driver of the market.

Online programs are accessible and easy ways to get rid of excessive fats. Also, the prevalence of chronic diseases such as hypertension and diabetes lead to obesity. A sedentary lifestyle without exercise and health activities leads to obesity. All these factors are driving the obese population to adopt management programs. This entire factor is expected to increase the overall market growth in the forecast period.

Obesity Management Market Segment Insights

Obesity Management Type Insights

The obesity management market segmentation, based on type, includes medications, surgery, and others. The medications segment further subdivided into Orlistat, Lorcaserin, Phentermine and Topiramate, Bupropion and Naltrexone, and Liraglutide. The surgery segment is also subdivided into laparoscopic adjustable gastric banding, gastric sleeve, and gastric bypass. The medications segment held the majority share in 2021. The medications are being used by the obese people along with diet, exercise, and behavior changes. The increasing approval rates for obesity management medications worldwide are driving segment growth.

June 2021: U.S. Food and Drug Administration approved Novo Nordisk’s (Denmark) Wegovy (semaglutide) injection for chronic weight management in adults.October 2022: Eli Lilly and Company (US) received U.S. Food and Drug Administration’s (FDA) fast track or tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities.

Figure 2: Obesity Management Market, by Type, 2021 & 2030 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Obesity Management Distribution Channel Insights

The obesity management market segmentation, based on distribution channel, includes hospital pharmacies, retail pharmacies and others. The hospital pharmacies segment dominated the market in 2021. This is due to increased hospitalization of obesity surgical procedures and increased number of hospital pharmacies worldwide. There is growing acceptance of non-invasive surgical procedures by the obese patients around the globe. It requires hospital admission of the patients. This fueling the segment growth.

September 2018: Ethicon, Inc. (US), a part of Johnson & Johnson, launched a new comprehensive surgical solution for bariatric revision surgery designed to help surgeons perform bariatric revision surgery with efficiency, precision and consistency. Wegovy, a well-known weight-loss treatment, has been introduced by Novo Nordisk in Germany, the company's first significant European market, hoping that Germans will spend several hundred euros out of pocket for a medication that their health insurance policies are currently not allowed to cover. The medication, which has been found to help patients lose body weight by about 15% when combined with exercise and a lifestyle change, is already accessible in the United States;

Obesity Management Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America accounts for the largest market share due to the increasing demand for minimally invasive surgeries, favorable reimbursement and rising awareness about obesity management.

Further, the major countries studied are: The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: Obesity Management Market Share By Region 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The North America obesity management market accounts for the largest market share due to the high population awareness about obesity management, presence of prominent market players and increased prevalence of obesity. For instance, according to Centers for Disease Control and Prevention, the obesity prevalence was 41.9% during 2017-2020 in the US. Also, according to data published in Healthline, more than one-third of adults have obesity in the US. Further, the US obesity management market held the largest market share and was the fastest-growing market in the North America region. Additionally, the Canada obesity management market held a significant market share in the North America region.

The Asia-Pacific obesity management market is expected to grow with a significant share. This is due to increasing adoption of sedentary lifestyle, increased disposable income of the people and rise in the obese population. Moreover, China obesity management market held the largest market share and was the fastest-growing market in the Asia-Pacific region. For instance, according to data published in AHA Journals, more than 1 in 7 individuals are obese in China. Similarly, India obesity management market held a significant share in the Asia-Pacific region.

Obesity Management Key Market Players & Competitive Insights

Major market players are adopting several business strategies to increase their market presence. They are significantly investing in R&D activities to expand their product portfolio, further driving the dental consumables market. In addition, the market players are adopting several strategic initiatives, such as new product launches, contractual agreements, mergers & acquisitions, increasing investments, and partnering with other players to expand their footprint.

Some key players in the market are Pfizer Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc. (UK), AstraZeneca (UK), and Herbalife Ltd. (US). Pfizer, Inc. (Pfizer) is a leading research-based biopharmaceutical company that applies science and resources to inventive treatments that extend and significantly improve lives. Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. Furthermore, the company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer’s obesity drug is in the pipeline (Phase II).

Key Companies in the Obesity Management market includes

• 
  

  Pfizer Inc. (US)

  
  


• 
  

  F. Hoffmann-La Roche Ltd (Switzerland)

  
  


• 
  

  GlaxoSmithKline plc. (UK)

  
  


• 
  

  AstraZeneca (UK)

  
  


• 
  

  Herbalife Ltd. (US)

  
  


• 
  

  Apollo Endosurgery (US)

  
  


• 
  

  Ethicon, Inc. (US)

  
  


• 
  

  Takeda Pharmaceutical Company (Japan)

  
  


• 
  

  VIVUS Inc. (US)

  
  


• 
  

  Currax Pharmaceuticals LLC (US) among others

  
  

Obesity Management Industry Developments

July 2022: VIVUS LLC (US) announced U.S. Food and Drug Administration (FDA) approval for QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in adolescents (12-17 years old).

July 2021: AstraZeneca (UK) partnered with Regeneron Pharmaceuticals (US) to develop small-molecule weight loss drugs.

Obesity Management Market Segmentation

Obesity Management Type Outlook

• 
  

  Medications

  
  
  
  
  • 
    

    Orlistat

    
    
  
  
  • 
    

    Lorcaserin

    
    
  
  
  • 
    

    Phentermine and Topiramate

    
    
  
  
  • 
    

    Bupropion and Naltrexone

    
    
  
  
  • 
    

    Liraglutide

    
    
  
  
  
  


• 
  

  Surgery

  
  
  
  
  • 
    

    Laparoscopic Adjustable Gastric Band

    
    
  
  
  • 
    

    Gastric Sleeve

    
    
  
  
  • 
    

    Gastric Bypass

    
    
  
  
  
  


• 
  

  Others

  
  

Obesity Management Distribution Channel Outlook

• 
  

  Hospital Pharmacies

  
  


• 
  

  Retail Pharmacies

  
  


• 
  

  Others

  
  

Obesity Management Regional Outlook

• 
  

  North America

  
  

• 
  
  
  
  • 
    

    US

    
    
  
  
  • 
    

    Canada

    
    
  
  
  
  

• 
  

  Europe

  
  

• 
  
  
  
  • 
    

    Germany

    
    
  
  
  • 
    

    France

    
    
  
  
  • 
    

    UK

    
    
  
  
  • 
    

    Italy

    
    
  
  
  • 
    

    Spain

    
    
  
  
  • 
    

    Rest of Europe

    
    
  
  
  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America